Headquartered in Wilmington, DE Fiscal year ends December NASDAQ: INCY incyte.com
Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines across three franchises: Hematology, Oncology, and Inflammation and Autoimmunity.
Its largest product is Jakafi (ruxolitinib), together with the once-daily Jakafi XR launched in 2026. It is a JAK1/JAK2 inhibitor marketed in the U.S. for polycythemia vera, myelofibrosis, and acute and chronic graft-versus-host disease.
Other marketed products include:
- Opzelura (ruxolitinib cream), for vitiligo and atopic dermatitis in the U.S. and Europe.
- Niktimvo (axatilimab), co-commercialized with Syndax for chronic GVHD.
- Zynyz (retifanlimab), a PD-1 antibody for anal canal and Merkel cell carcinoma, licensed from MacroGenics.
- Monjuvi/Minjuvi (tafasitamab), for lymphomas, licensed from Xencor.
- Pemazyre (pemigatinib), an FGFR inhibitor.
- Iclusig (ponatinib), sold in Europe and other territories under license from Takeda.
Incyte also earns royalties on Novartis' Jakavi, Lilly's Olumiant and Novartis' Tabrecta, plus milestone revenue from collaborators.
Its late-stage pipeline includes:
- INCA033989, a mutCALR antibody for essential thrombocythemia and myelofibrosis.
- Latarcibart, for von Willebrand disease, acquired with Vega Therapeutics in July 2026.
- INCB161734, a KRAS G12D inhibitor for pancreatic and colorectal cancer.
- INCA33890, a TGFβR2×PD-1 bispecific for colorectal cancer, developed with Merus/Genmab.
- INCB123667, a CDK2 inhibitor for ovarian cancer.
- Povorcitinib, an oral JAK1 inhibitor branded Povofortay, under review for hidradenitis suppurativa. Updated
Opzelura sales grew 36% as Jakafi's patent clock keeps ticking, and that is the number that decides what this company looks like after 2029. The quarter's loss is entirely the Vega Therapeutics IPR&D charge, and management still raised full-year sales guidance.
Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.5% after a spooky day yesterday, as all major indices ended lower and most on Wall Street pointed…
Tempus AI (NASDAQ:TEM | TEM Price Prediction) reports third-quarter results around Nov. 2. The company has a $1.5 billion Personalis (NASDAQ:PSNL) deal pending, and shares are down 20.36% over the past month.…
Wall Street is firing on all cylinders this Thursday, with major upgrades hitting healthcare, telecom, and e-commerce while Treasury bond buybacks shake up yields and send gold surging past $4,500. Find out…
Pre-Market Stock Futures: Futures are trading mixed as we prepare to finish the last full week of the second quarter. We finished a wild holiday-shortened trading week last Thursday, as Friday was…
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, “Fool me once, shame on you; fool me twice, shame on me.”…
Pre-Market Stock Futures: Futures are trading lower once again after another up-and-down day on Wall Street. Once again, the rotation narrative rang out as software and chip stocks were hit hard, and…
Friday's top analyst upgrades and downgrades included Builders FirstSource, CVS Health, DHT, Incyte, McDonald's, Newell Brands, PacWest Bancorp, Wingstop and ZoomInfo Technologies.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Amcor, Caesars Entertainment, CarMax, Chewy, Marriott International, Microsoft, Molson Coors Beverage, NXP Semiconductors and Uber Technologies.
Tuesday's top analyst upgrades and downgrades included American Homes 4 Rent, Block, Catalent, Cushman & Wakefield, Hasbro, McDonald's, NetApp, Pioneer Natural Resources, Regions Financial, Southwestern Energy, Tyson Foods, Warner Bros. Discovery and…
Tuesday's top analyst upgrades and downgrades included Alphabet, Caterpillar, Corning, Digital Realty Trust, Dish Network, KeyCorp, Nvidia, Pinterest, Roku, Tesla and Wynn Resorts.
Monday's top analyst upgrades and downgrades included Altria, Block, Coinbase Global, Deere, First Horizon, KB Home, Pfizer, PNC Financial Services, RingCentral, Uber Technologies znd Zoom Video Communications.
Tuesday's top analyst upgrades and downgrades included Amgen, Caterpillar, CF Industries, Coinbase Global, Fastly, Match, Newmont, Okta, Progressive, Toast, Under Armour, Walt Disney and Zim Integrated Shipping Services.
More AI-enabled search chatbots to compete with Google, and Manchester United may have found a buyer.
Wednesday's top analyst upgrades and downgrades included Alphabet, Bank of America, Dollar General, Edwards Lifesciences, Fortinet, Fox, Halliburton, LyondellBasell Industries, Paramount Global, SoFi Technologies and Truist Financial.
Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines across three franchises: Hematology, Oncology, and Inflammation and Autoimmunity. Its largest product is Jakafi (ruxolitinib), together with the once-daily Jakafi XR launched in 2026.
24/7 Wall St.'s 12-month price target for INCY is $199.80, rated Buy. The Wall Street consensus target is $129.54. INCY price prediction →
